Ibex Wealth Advisors Acquires New Shares in Pfizer Inc. $PFE

Ibex Wealth Advisors acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 341,147 shares of the biopharmaceutical company’s stock, valued at approximately $8,495,000.

Other institutional investors have also recently bought and sold shares of the company. Horizon Financial Services LLC boosted its position in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new stake in Pfizer during the fourth quarter valued at $26,000. YANKCOM Partnership acquired a new stake in Pfizer during the fourth quarter valued at $28,000. HFM Investment Advisors LLC boosted its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Abound Financial LLC acquired a new stake in Pfizer during the fourth quarter valued at $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $26.04 on Wednesday. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a market capitalization of $148.41 billion, a PE ratio of 19.88 and a beta of 0.34. The stock has a 50-day simple moving average of $26.34 and a 200 day simple moving average of $26.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the previous year, the firm earned $0.92 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer’s payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on PFE shares. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. Barclays began coverage on Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.82.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s obesity pipeline gained traction after detailed Phase 2b data for berobenatide showed proof of concept, favorable tolerability, and low reported adverse events. Pfizer has already moved the program into Phase 3, which could support longer-term growth expectations. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
• Positive Sentiment: CEO comments that Pfizer could return to high-single-digit growth suggest the business may be stabilizing faster than some investors expected, reinforcing the idea that the company’s recent weakness may be overdone. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
• Neutral Sentiment: Pfizer is drawing heavy investor interest and analyst coverage, with recent research pieces focusing on its discounted valuation, pipeline prospects, and post-COVID growth outlook. That keeps sentiment active, but the articles do not point to a single new catalyst. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Pfizer also remained in the news through broader healthcare coverage and research roundups, but these items appear informational rather than stock-moving. Top Research Reports for Pfizer, Altria & Newmont Corp.
• Negative Sentiment: Some coverage continues to frame Pfizer as a value stock facing fading COVID revenue and looming patent-cliff pressure, which reminds investors of the company’s near-term growth challenges even as pipeline efforts progress. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.